Spyre Therapeutics (SYRE) Accumulated Expenses (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Accumulated Expenses data on file, last reported at $29.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 34.81% year-over-year to $29.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.2 million (up 34.81% YoY) and the FY2025 annual result came in at $26.9 million, down 2.76% from the prior year.
• Accumulated Expenses rose to $29.2 million in Q1 2026, from $26.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $29.2 million in Q1 2026 to a low of $2.4 million in Q1 2022.
• A 5-year average of $15.3 million and a median of $13.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses sank 70.56% — and 2024, when it jumped 655.83%.
• Tracing SYRE's Accumulated Expenses over 5 years: stood at $12.8 million in 2022, then gained by 2.11% to $13.1 million in 2023, then surged by 111.41% to $27.7 million in 2024, then retreated by 2.76% to $26.9 million in 2025, then climbed by 8.21% to $29.2 million in 2026.
• The last three Accumulated Expenses figures came in at $29.2 million (Q1 2026), $26.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.